Manufacturing / Pharmaceutical Preparations
MapLight Therapeutics, Inc.
MPLT
$8.83
-$0.32 (-3.50%)
Price as of Oct 9, 2026 21:39 UTC
520 M
Market Cap (Small Cap)
Dec 01
Next Earnings
Technical Signals
as of Oct 7
Bearish
0 of 7
Trend
- Above 20-day average $10.78
- Above 50-day average $14.05
- Above 200-day average $18.88 · -50.4%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) Down · 32d ago
- Momentum cross (20/50) Down · 49d ago
Volume
- Below-average volume 0.6x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Heat Map
Delta-risk grid for MPLT options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
13 buys
139 sells
| Date | Insider | Title | Type | Shares | Value | Since Trade |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Hanson Kristopher | Sell | 16,509 | $192,660 | -21.6% | |
| Aug 17, 2026 | Lillie James Woodruff | Grant | 7,730 | $0 | -18.7% | |
| Aug 17, 2026 | Kreitzer Anatol | Grant | 24,455 | $0 | -18.7% | |
| Aug 17, 2026 | Kreitzer Anatol | Grant | 6,020 | $0 | -18.7% | |
| Aug 17, 2026 | Foff Erin Pennock | Grant | 54,240 | $0 | -18.7% | |
| Aug 17, 2026 | Foff Erin Pennock | Grant | 13,360 | $0 | -18.7% | |
| Aug 17, 2026 | Hanson Kristopher | Grant | 31,395 | $0 | -18.7% | |
| Aug 17, 2026 | Hanson Kristopher | Grant | 7,730 | $0 | -18.7% | |
| Aug 17, 2026 | Lillie James Woodruff | Grant | 31,395 | $0 | -18.7% | |
| Aug 17, 2026 | GILLIS JONATHAN | Grant | 2,813 | $0 | -18.7% |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Sep 01, 2026 | Q2 2026 | -$1.36 | |||
| Jun 30, 2026 | Q2 2026 | -$1.34 | -$1.32 | +1.5% | Beat |
| Mar 31, 2026 | Q1 2026 | -$1.12 | -$1.34 | -20.1% | Miss |
| Dec 31, 2025 | Q4 2025 | -$0.98 | -$2.47 | -151.7% | Miss |
| Sep 30, 2025 | Q3 2025 | -$1.76 | -$37.18 | -2013.1% | Miss |
Track MPLT with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for MPLT and your entire portfolio.